Sandbox/Afib: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 107: Line 107:
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | }}
{{Family tree/end}}
{{Family tree/end}}
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="3"| {{fontcolor|#FFF|CHA2DS2-VASc}}
|-
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Variable'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Score'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Age ≥75 years''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Age 65-74 years''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Female sex''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Diabetes mellitus''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Hypertension''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Congestive heart failure''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Stroke/TIA/Thromboembolism''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''2'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Vascular disease (prior MI, PAD, or aortic plaque)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1'''''
|-
|-
|}
|}


==Do's & Dont's==
==Do's & Dont's==

Revision as of 16:19, 1 May 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

 
 
 
 
 
 
 
 
 
 
 
 

New onset atrial fibrillation:
❑ The presentation can be any of the following:

❑ Paroxysmal and stop spontaneously
❑ Persistent and stop only with cardioversion
❑ Permanent and present for prolonged periods
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Stable:
❑ Asymptomatic

❑ Mild to moderate symptoms
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient require heart rate control therapy?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Identify the underlying etiology and treat accordingly
❑ Proceed with cardioversion & anticoagulation strategy as shown below
 
 
Does the patient have any evidence of an accessory pathway (pre-exitation syndrome)
 
 
 
 
 
Does the patient has any symptoms and signs of pulmonary edema?

Dyspnea
Crackles

Chest X-ray showing pulmonary edema
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
Yes
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient has any evidence of heart failure with reduced EF
 
❑ IV procainamide or ibutilide
Catheter ablation if the accessory pathway has a short refractory period that allows rapid antegrade conduction
 
Manage pulmonary edema:

❑ Initiate oxygen therapy
❑ High doze IV diuretics
❑ BP management

❑ SBP 85 - 100 mm Hg (dobutamine or milrinone)
❑ SBP < 85 mm Hg (dopamine and norepinephrine)
 
Immediate DC cardioversion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
After initial pulmonary edema management proceed with DC cardioversion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heart rate control:

Digoxin
❑ Oral vs intravenous are based upon the clinical urgency

 
Heart rate control:

Beta blockers or CCB's
❑ Oral vs intravenous are based upon the clinical urgency

 
 
 
Successful
 
Unsuccessful
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient respond or the arrhythmia terminate (sinus rhythm)?
 
 
 
 
 
Identify the underfying cause and treat accordingly
 
Repeated attempts may be made after adjusting the location of the electrodes or applying pressure over the electrodes, or following administration of an antiarrhythmic medication
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identify the other underlying etiologies and treat accordingly
 
Oral vs intravenous amiodarone according to the clinical urgency
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proceed with the anticoagulation strategy as shown below
 
Does the patient respond or the arrhythmia terminate (sinus rhythm)?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Identify the underlying etiology and treat accordingly
❑ Proceed with anticoagulation strategy as shown below
 
Proceed with the cardioversion strategy as shown below
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Cardioversion Strategy

 
 
 
 
 
 
 
 
 

Does the patient with new onset AF has any contraindication for cardioversion :
❑ Asymptomatic elderly patients (>80 years) with multiple comorbidities
❑ Patients with high risk of bleeding

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assess stroke risk to initiate long term anticoagulation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ <48 hours
 
 
 
 
 
 
 
❑ >48 hours
❑ Unknown
❑ Prior history of a thromboembolic event
❑ Prior history of TEE evidence of left atrial thrombus
❑ Mitral valve disease or significant cardiomyopathy or heart failure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV heparin
 
 
 
 
 
3 week oral anticoagulation
 
 
 
TEE
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardioversion
 
 
 
 
 
 
 
 
 
 
No LA thrombus
 
 
LA thrombus
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sinus rhythm
 
Atrial fibrillation
 
 
 
 
 
 
 
 
Heparin
 
 
3 week oral anticoagulation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assess stroke risk to initiate long term anticoagulation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat TEE showing no LA thrombus
 
Repeat TEE showing LA thrombus
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardioversion
 
 
 
 
Initiate rate control
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Atrial fibrillation
 
Sinus rhythm
 
 
Assess stroke risk to initiate long term anticoagulation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat cardioversion or use AV nodal blocking agents
 
 
 
 
 
Assess stroke risk to initiate long term anticoagulation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sinus rhythm
 
Atrial fibrillation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assess stroke risk to initiate long term anticoagulation
 
Initiate 4 week anticoagulation therapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


CHA2DS2-VASc
Variable Score
Age ≥75 years 1
Age 65-74 years 1
Female sex 1
Diabetes mellitus 1
Hypertension 1
Congestive heart failure 1
Stroke/TIA/Thromboembolism 2
Vascular disease (prior MI, PAD, or aortic plaque) 1


Do's & Dont's

  • IV amiodarone or digoxin may be considered to slow a rapid ventricular response in patients with ACS and AF associated with severe LV dysfunction and HF.
  • Avoid beta blockers to control the ventricular rate in patients with AF and chronic obstructive pulmonary disease.
  • Avoid amiodarone, adenosine, digoxin, or calcium channel antagonists (oral or intravenous) in patients with WPW syndrome who have pre-excited AF.
  • In AF with HF, it is reasonable to perform AV node ablation with ventricular pacing to control heart rate when pharmacological therapy is insufficient or not tolerated.
  • For patients with AF and rapid ventricular response causing or suspected of causing tachycardia induced cardiomyopathy, it is reasonable to achieve rate control by either AV nodal blockade or a rhythm-control strategy.


References


Template:WikiDoc Sources